Allogeneic bone marrow transplantation for refractory mantle cell lymphoma

Kröger, N.; Hoffknecht, M.; Krüger, W.; Zeller, W.; Renges, H.; Stute, N.; Zschaber, R.; Zander, A. R.
October 2000
Annals of Hematology;Oct2000, Vol. 79 Issue 10, p578
Academic Journal
We report about a 28-year-old woman with relapsed mantle cell lymphoma (MCL, centrocytic lymphoma according to the Kiel classification) refractory to salvage chemotherapy. The patient underwent allogeneic bone marrow transplantation from a HLA-identical brother after myeloablative chemotherapy consisting of busulfan, etoposide, and cyclophosphamide. The patient experienced hepatic toxicity (grade I), mucositis (grade II) according the Bearman scale, and graft versus host disease of the skin (grade II) and showed stable engraftment with complete chimerism on day 15 after bone marrow transplantation. Eight years after transplantation, the patient is still disease free and in good condition without any late side effects. This report suggests a curative potential of allogeneic stem cell transplantation in MCL.


Related Articles

  • Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin�s lymphoma. Bernard, M; Dauriac, C; Dr�nou, B; Leberre, C; Branger, B; Fauchet, R; Le Pris�, P Y; Lamy, T // Bone Marrow Transplantation;2/15/99, Vol. 23 Issue 4, p329 

    Relapsed or very aggressive high-grade NHL and refractory low-grade NHL have a poor clinical outcome. Autologous BMT may be used but is of limited efficacy in these cases. Allogeneic BMT offers the advantage of tumour-free bone marrow and a possible GVL effect. Between 1987 and 1996, 13 patients...

  • First-line therapy of advanced chronic lymphocytic leukemia. Wilhelm, M.; Tony, H.-P.; Rueckle-Lanz, H.; Wilms, K. // Leukemia (08876924);Apr97 Supplement 2, Vol. 11, pS14 

    There is general agreement that patients with advanced chronic lymphocytic leukemia (CLL) should be treated if they develop anemia or thrombocytopenia. The combination of chlorambucil (CLB) and prednisone is often used for first-line therapy of these patients, but compared to monotherapy with...

  • New Leukemia Therapies. Danner, Valerie; Serafin, Amanda Grace // Access;May/Jun2002, Vol. 16 Issue 5, p10 

    Reports on the effect of chemotherapy and bone marrow transplants in normal and abnormal cells in the U.S. Development of highly refined therapies; Introduction of Imatinib mesylate to treat chronic myeloid leukemia (CML); Goal for the treatment of CML.

  • Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Przepiorka, D; Khouri, I; Thall, P; Mehra, R; Lee, M-S; Ippoliti, C; Giralt, S; Gajewski, J; van Besien, K; Andersson, B; Körbling, M; Deisseroth, A B; Champlin, R // Bone Marrow Transplantation;5/15/99, Vol. 23 Issue 10, p977 

    Thirty-six adults with chronic myelogenous leukemia (CML) in second or greater chronic phase, accelerated phase, or blast crisis underwent marrow or blood stem cell transplantation from an HLA-matched sibling using high-dose thiotepa, busulfan and cyclophosphamide (TBC) as the preparative...

  • Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Ephrem, A.; Misra, N.; Hassan, G.; Dasgupta, S.; Delignat, S.; Van Huyen, J.-P. Duong; Chamat, S.; Prost, F.; Lacroix-Desmazes, S.; Kavery, S. V.; Kazatchkine, M. D. // Clinical & Experimental Medicine;Dec2005, Vol. 5 Issue 4, p135 

    Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic...

  • Bone Marrow Hypoplasia Responsive to Testosterone Therapy in a Patient With Panhypopituitarism: Need for Adherence to Androgen Replacement. Manal Badawi; Farah Salih; Abdel Al-Humaidi; Mohamed El Khalifa; Tarik Elhadd // Endocrine Practice; 

    Objective: To describe the case of a young Saudi male patient with long-term panhypopituitarism and pancytopenia attributable to poor adherence to androgen replacement therapy, which resolved after institution of testosterone treatment and recurred after another interval of poor adherence to...

  • Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Merouani, Aicha; Shpall, Elizabeth J.; Jones, Roy B.; Archer, Philip G.; Schrier, Robert W. // Kidney International;Sep1996, Vol. 50 Issue 3, p1026 

    Autologous and allogeneic bone marrow grafting both require cytoreductive therapy but only the allogeneic procedure requires immunosuppressive agents. Allogeneic bone marrow transplantation has been reported to be associated with a high incidence of both renal failure and veno-occlusive disease...

  • Incidence of Acute Oral Sequelae in Pediatric Patients Undergoing Chemotherapy. Hong, C. H.; Brennan, M. T.; Lockhart, P. B. // Pediatric Dentistry;Sep/Oct2009, Vol. 31 Issue 5, p420 

    Purpose: The purpose of this literature review was to assess the incidence of acute oral sequelae in children receiving cytotoxic therapy. Methods: The dental literature was searched using 3 electronic databases--Cochrane, Medline, and Embase--from 1966 to 2006 and was limited to articles...

  • Complex partial status epilepticus after bone marrow transplantation for non-Hodgkin’s lymphoma. Wszolek, Z K; Steg, R E; Armitage, J O // Bone Marrow Transplantation;3/15/97, Vol. 19 Issue 6, p637 

    We report a case of complex partial status epilepticus presenting as recurring episodes of altered mental status and subtle automatisms after bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma. Early recognition of complex partial status epilepticus as a cause of altered mental...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics